Prevention of autoimmune diabetes by FTY720 in nonobese diabetic mice

Transplantation

Volumn 74, Issue 12, 2002, Pages 1684-1686

  Maki, Takashi ^a,b   Gottschalk, Rita ^a   Monaco, Anthony P ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FINGOLIMOD;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG POTENCY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0037184806     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200212270-00006     Document Type: Article

References (14)

1. Suzuki S, Enosawa S, Kakefuda T, et al. A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation. Transplantation 1996; 61:200-205.
2. Matsuura M, Imayoshi T, Okumoto T. Effect of FTY720, a novel immunosuppressant, on adjuvant- and collagen-induced arthritis in rats. Int J Immunopharmacol 2000; 22: 323-331.
3. Kitabayashi H, Isobe M, Watanabe N, et al. FTY720 prevents development of experimental autoimmune myocarditis through reduction of circulating lymphocytes. J Cardiovasc Pharmacol 2000; 35: 410-416.
4. Kurose S, Ikeda E, Tokiwa M, et al. Effects of FTY720, a novel immunosuppressant on experimental autoimmune uveoretinitis in rats. Exp Eye Res 2000; 70: 7-15.
5. Hozumi Y, Kobayashi E, Miyata M, et al. Immunotherapy for experimental rat autoimmune thyroiditis using a novel immunosuppressant, FTY720. Life Sci 1999; 65: 1739-1745.
6. Chiba K, Yanagawa Y, Masubuchi Y, et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol 1998; 160: 5037-5044.
7. Yanagawa Y, Hoshino Y, Kataoka H, et al. FTY720, a novel immunosuppressant possessing unique mechanisms. II. FTY720 prolongs skin allograft survival by decreasing T-cell infiltration into grafts but not cytokine production in vivo. J Immunol 1998; 160: 5493-5499.
8. Suzuki S, Li X-K, Enosawa S, et al. A new immunosuppressant, FTY720, induces bcl-2 associated apoptotic cell death in human lymphocytes. Immunology 1996; 89: 518-523.
9. Makino S, Kunimoto K, Muraoka Y, et al. Breeding of a non-obese diabetic strain of mice. Exp Animal 1980; 29: 1-13.
10. Bedossa P, Bendelac A, Bach J-F, et al. Syngeneic T cell transfer of diabetes into NOD newborn mice: In situ studies of the autoimmune steps leading to insulin-producing cell destruction. Eur J Immunol 1989; 19: 1947-1951.
11. Harada M, Makino S. Promotion of spontaneous diabetes in non-obese diabetes-prone mice by cyclophosphamide. Diabetologia 1984; 27: 604-606.
12. Fu F, Hu S, Deleo J, et al. Long-term islet graft survival in streptozotocin-and autoimmune-induced diabetes models by immunosuppressive and potential insulinotropic agent FTY720. Transplantation 2002; 73: 1425-1430.
13. Shizuru JA, Taylor-Edwards C, Banks BA, et al. Immunotherapy of the nonobese diabetic mouse: Treatment with an antibody to T-helper lymphocytes. Science 1988; 240: 659-662.
14. Pinschewer DD, Ochsenbein AF, Odermatt B, et al. FTY720 immunosuppression impairs effector T-cell peripheral homing without affecting induction, expansion, and memory. J Immunol 2000; 164: 5761-5770.